Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194042
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Selma-Royo, Marta | - |
dc.contributor.author | Bäuerl, Christine | - |
dc.contributor.author | Mena-Tudela, Desirée | - |
dc.contributor.author | Aguilar-Camprubí, Laia | - |
dc.contributor.author | Pérez-Cano, Francisco J. | - |
dc.contributor.author | Parra-Llorca, Anna | - |
dc.contributor.author | Lerin, Carles | - |
dc.contributor.author | Martínez Costa, Cecilia | - |
dc.contributor.author | Collado, Maria Carmen | - |
dc.date.accessioned | 2023-02-23T11:51:07Z | - |
dc.date.available | 2023-02-23T11:51:07Z | - |
dc.date.issued | 2022-04-21 | - |
dc.identifier.issn | 1756-994X | - |
dc.identifier.uri | http://hdl.handle.net/2445/194042 | - |
dc.description.abstract | Background: Breast milk is a vehicle to transfer protective antibodies from the lactating mother to the neonate. After SARS-CoV-2 infection, virus-specific IgA and IgG have been identified in breast milk, however, there are limited data on the impact of different COVID-19 vaccine types in lactating women. This study is aimed to evaluate the time course of induction of SARS-CoV-2-specific IgA and IgG in breast milk after vaccination. Methods: In this prospective observational study in Spain, 86 lactating women from priority groups receiving the vaccination against SARS-CoV-2 were included. Breast milk samples were collected longitudinally at seven or eight-time points (depending on vaccine type). A group with confirmed SARS-CoV-2 infection (n=19) and a group of women from pre-pandemic time (n=20) were included for comparison. Results: Eighty-six vaccinated lactating women [mean age, 34.6 ± 3.7 years] of whom 96% were Caucasian and 92% were healthcare workers. A total number of 582 milk samples were included, and vaccine distribution was BioNTech/Pfizer (BNT162b2, n=34), Moderna (mRNA-1273, n=20), and AstraZeneca (ChAdOx1 nCoV-19, n=32). For each vaccine, 7 and 8 longitudinal time points were collected from baseline up to 30 days after the second dose for mRNA vaccines and adenovirus-vectored vaccines, respectively. A strong reactivity was observed for IgG and IgA after vaccination mainly after the 2nd dose. The presence and persistence of specific SARS-CoV-2 antibodies in breast milk were dependent on the vaccine type, with higher IgG and IgA levels in mRNA-based vaccines when compared to AstraZeneca, and on previous virus exposure. High intra- and inter-variability were observed, being relevant for IgA antibodies. In milk from vaccinated women, anti-SARS-CoV-2 IgG was significantly higher while IgA levels were lower than in milk from COVID-19-infected women. Women with previous COVID-19 increased their IgG antibodies levels after the first dose to a similar level observed in vaccinated women after the second dose. Conclusions: COVID-19 vaccination induced anti-SARS-CoV-2 IgA and IgG in breast milk with higher levels after the 2nd dose. Levels of anti-SARS-CoV-2 IgA and IgG are dependent on the vaccine type. Further studies are warranted to demonstrate the protective antibody effect against COVID-19 in infants from vaccinated and infected mothers. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01043-9 | - |
dc.relation.ispartof | Genome Medicine, 2022, vol. 14, num. 1, p. 42 | - |
dc.rights | cc-by (c) Selma-Royo, Marta et al., 2022 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Bioquímica i Fisiologia) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Llet materna | - |
dc.subject.classification | Vacunes | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Breast milk | - |
dc.subject.other | Vaccines | - |
dc.title | Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 730301 | - |
dc.date.updated | 2023-02-23T11:51:07Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Fisiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
730301.pdf | 2.11 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License